US20130029962A1 - Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands - Google Patents

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands Download PDF

Info

Publication number
US20130029962A1
US20130029962A1 US13/557,941 US201213557941A US2013029962A1 US 20130029962 A1 US20130029962 A1 US 20130029962A1 US 201213557941 A US201213557941 A US 201213557941A US 2013029962 A1 US2013029962 A1 US 2013029962A1
Authority
US
United States
Prior art keywords
methyl
pyrazol
alkyl
pyridin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/557,941
Other languages
English (en)
Inventor
Robert Frank
Gregor Bahrenberg
Thomas Christoph
Bernhard Lesch
Jeewoo Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46640622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20130029962(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to US13/557,941 priority Critical patent/US20130029962A1/en
Assigned to GRUENENTHAL GMBH reassignment GRUENENTHAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAHRENBERG, GREGOR, CHRISTOPH, THOMAS, LEE, JEEWOO, FRANK, ROBERT, LESCH, BERNHARD
Publication of US20130029962A1 publication Critical patent/US20130029962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or inhibition of pain and further diseases and/or disorders.
  • the subtype 1 vanilloid receptor (VR1/TRPV1), which is often also referred to as the capsaicin receptor, is a suitable starting point for the treatment of pain, in particular of pain selected from the group consisting of acute pain, chronic pain, neuropathic pain and visceral pain.
  • This receptor is stimulated inter alia by vanilloids such as capsaicin, heat and protons and plays a central role in the formation of pain.
  • Another object of the invention was to provide new compounds with vanilloid receptor 1 activity which are suitable in particular as pharmacological active ingredients in pharmaceutical compositions.
  • substituted compounds of general formula (I), as given below display outstanding affinity to the subtype 1 vanilloid receptor (VR1/TRPV1 receptor) and are therefore particularly suitable for the inhibition and/or treatment of disorders or diseases which are at least partially mediated by vanilloid receptors 1 (VR1/TRPV1).
  • the present invention therefore relates to a substituted compound of general formula (I),
  • OCF 3 OCF 2 H; OCFH 2 ; OCF 2 Cl; OCFCl 2 ; OR 0 ; O—C( ⁇ O)—R 0 ; O—C( ⁇ O)—O—R 0 ; O—(C ⁇ O)—NH—R 0 ; O—C( ⁇ O)—N(R 0 ) 2 ; O—S( ⁇ O) 2 —R 0 ; O—S( ⁇ O) 2 —OH; O—S( ⁇ O) 2 —OR 0 ; O—S( ⁇ O) 2 —NH 2 ; O—S( ⁇ O) 2 —NHR 0 ; O—S( ⁇ O) 2 —N(R 0 ) 2 ; NH 2 ; NHR 0 ; N(R 0 ) 2 ; NH—C( ⁇ O)—R 0 ; NH—C( ⁇ O)—O—R 0 ; NH—C( ⁇ O)—O—R 0 ; NH—
  • single stereoisomer comprises in the sense of this invention an individual enantiomer or diastereomer.
  • mixture of stereoisomers comprises in the sense of this invention the racemate and mixtures of enantiomers and/or diastereomers in any mixing ratio.
  • physiologically acceptable salt comprises in the sense of this invention a salt of at least one compound according to the present invention and at least one physiologically acceptable acid or base.
  • C 1-10 aliphatic residue comprises in the sense of this invention acyclic saturated or unsaturated aliphatic hydrocarbon residues, which can be branched or unbranched and also unsubstituted or mono- or polysubstituted, which contain 1 to 10, or 1 to 8, or 1 to 4 carbon atoms respectively, i.e.
  • Alkenyls comprise at least one C—C double bond (a C ⁇ C-bond) and alkynyls comprise at least one C—C triple bond (a C ⁇ C-bond).
  • aliphatic residues are selected from the group consisting of alkanyl (alkyl) and alkenyl residues, more preferably are alkanyl (alkyl) residues.
  • Preferred C 1-10 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl and n-decyl.
  • Preferred C 1-8 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl and n-octyl.
  • Preferred C 1-4 alkanyl residues are selected from the group consisting of methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and tert.-butyl.
  • Preferred C 2-10 alkenyl residues are selected from the group consisting of ethenyl (vinyl), propenyl (—CH 2 CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C( ⁇ CH 2 )—CH 3 ), butenyl, pentenyl, hexenyl heptenyl, octenyl, nonenyl and decenyl.
  • Preferred C 2-8 alkenyl residues are selected from the group consisting of ethenyl (vinyl), propenyl (—CH 2 CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C( ⁇ CH 2 )—CH 3 ), butenyl, pentenyl, hexenyl heptenyl and octenyl.
  • Preferred C 2-4 alkenyl residues are selected from the group consisting of ethenyl (vinyl), propenyl (—CH 2 CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C( ⁇ CH 2 )—CH 3 ) and butenyl.
  • Preferred C 2-10 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH 2 —C ⁇ CH, —C ⁇ C—CH 3 ), butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl.
  • Preferred C 2-8 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH 2 —C ⁇ CH, —C ⁇ C—CH 3 ), butynyl, pentynyl, hexynyl, heptynyl and octynyl.
  • Preferred C 2-4 alkynyl residues are selected from the group consisting of ethynyl, propynyl (—CH 2 —C ⁇ CH, —C ⁇ C—CH 3 ) and butynyl.
  • C 3-6 cycloaliphatic residue” and “C 3-10 cycloaliphatic residue” mean for the purposes of this invention cyclic aliphatic hydrocarbons containing 3, 4, 5 or 6 carbon atoms and 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, respectively, wherein the hydrocarbons in each case can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or polysubstituted.
  • the cycloaliphatic residues can be bound to the respective superordinate general structure via any desired and possible ring member of the cycloaliphatic residue.
  • the cycloaliphatic residues can also be condensed with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, i.e. with cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residues, which in each case can in turn be unsubstituted or mono- or polysubstituted.
  • C 3-10 cycloaliphatic residue can furthermore be singly or multiply bridged such as, for example, in the case of adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl.
  • Preferred C 3-10 cycloaliphatic residues are selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl,
  • C 3-6 cycloaliphatic residues are selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl.
  • Particularly preferred C 3-10 cycloaliphatic and C 3-6 cycloaliphatic residues are C 6-6 cycloaliphatic residues such as cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl.
  • 3-6-membered heterocycloaliphatic residue and “3-10-membered heterocycloaliphatic residue” mean for the purposes of this invention heterocycloaliphatic saturated or unsaturated (but not aromatic) residues having 3-6, i.e. 3, 4, 5 or 6 ring members, and 3-10, i.e.
  • ring members respectively, in which in each case at least one, if appropriate also two or three carbon atoms are replaced by a heteroatom or a heteroatom group each selected independently of one another from the group consisting of O, S, S( ⁇ O) 2 , N, NH and N(C 1-8 alkyl) such as N(CH 3 ), preferably are replaced by a heteroatom or a heteroatom group each selected independently of one another from the group consisting of O, S, N, NH and N(C 1-8 alkyl) such as N(CH 3 ), wherein the ring members can be unsubstituted or mono- or polysubstituted.
  • the heterocycloaliphatic residue can be bound to the superordinate general structure via any desired and possible ring member of the heterocycloaliphatic residue if not indicated otherwise.
  • the heterocycloaliphatic residues can also be condensed with further saturated, (partially) unsaturated (hetero)cycloaliphatic or aromatic or heteroaromatic ring systems, i.e. with cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residues, which can in turn be unsubstituted or mono- or polysubstituted.
  • Preferred heterocycloaliphatic residues are selected from the group consisting of azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dioxepanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, oxazepanyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, t
  • aryl means for the purpose of this invention aromatic hydrocarbons having 6 to 14, i.e. 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring members, preferably having 6 to 10, i.e. 6, 7, 8, 9 or 10 ring members, including phenyls and naphthyls.
  • Each aryl residue can be unsubstituted or mono- or polysubstituted, wherein the aryl substituents can be the same or different and in any desired and possible position of the aryl.
  • the aryl can be bound to the superordinate general structure via any desired and possible ring member of the aryl residue.
  • aryl residues can also be condensed with further saturated, (partially) unsaturated, (hetero)cycloaliphatic, aromatic or heteroaromatic ring systems, i.e. with a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residue, which can in turn be unsubstituted or mono- or polysubstituted.
  • condensed aryl residues are benzodioxolanyl and benzodioxanyl.
  • aryl is selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, fluorenyl and anthracenyl, each of which can be respectively unsubstituted or mono- or polysubstituted.
  • a particularly preferred aryl is phenyl, unsubstituted or mono- or polysubstituted.
  • heteroaryl for the purpose of this invention represents a 5 or 6-membered cyclic aromatic residue containing at least 1, if appropriate also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are each selected independently of one another from the group S, N and O and the heteroaryl residue can be unsubstituted or mono- or polysubstituted; in the case of substitution on the heteroaryl, the substituents can be the same or different and be in any desired and possible position of the heteroaryl.
  • the binding to the superordinate general structure can be carried out via any desired and possible ring member of the heteroaryl residue if not indicated otherwise.
  • the heteroaryl can also be part of a bi- or polycyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated, (hetero)cycloaliphatic or aromatic or heteroaromatic rings, i.e. with a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl residue, which can in turn be unsubstituted or mono- or polysubstituted.
  • heteroaryl residue is selected from the group consisting of benzofuranyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazoyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pyrazolyl, pyridyl (2-pyridyl,
  • the term “bridged via a C 1-4 aliphatic group or via a C 1-8 aliphatic group” with respect to residues as aryl, heteroaryl, a heterocycloaliphatic residue and a cycloaliphatic residue mean for the purpose of the invention that these residues have the above-defined meanings and that each of these residues is bound to the respective superordinate general structure via a C 1-4 aliphatic group or via a C 1-8 aliphatic group, respectively.
  • the C 1-4 aliphatic group and the C 1-8 -aliphatic group can in all cases be branched or unbranched, unsubstituted or mono- or polysubstituted.
  • the C 1-4 aliphatic group can in all cases be furthermore saturated or unsaturated, i.e. can be a C 1-4 alkylene group, a C 2-4 alkenylene group or a C 2-4 alkynylene group.
  • the C 1-4 -aliphatic group is a C 1-4 alkylene group or a C 2-4 alkenylene group, more preferably a C 1-4 alkylene group.
  • the C 1-8 -aliphatic group is a C 1-8 alkylene group or a C 2-8 alkenylene group, more preferably a C 1-8 alkylene group.
  • Preferred C 1-4 alkylene groups are selected from the group consisting of —CH 2 —, —CH 2 —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —, —CH(CH 3 )—CH 2 —, —CH(CH 2 CH 3 )—, —CH 2 —(CH 2 ) 2 —CH 2 —, —CH(CH 3 )—CH 2 —CH 2 —, —CH 2 —CH(CH 3 )—CH 2 —, —CH(CH 3 )—CH(CH 3 )—, —CH(CH 2 CH 3 )—CH 2 —, —C(CH 3 ) 2 —CH 2 —, —CH(CH 2 CH 2 CH 3 )— and —C(CH 3 )(CH 2 CH 3 )—.
  • Preferred C 2-4 alkenylene groups are selected from the group consisting of —CH ⁇ CH—, —CH ⁇ CH—CH 2 —, —C(CH 3 ) ⁇ CH 2 —, —CH ⁇ CH—CH 2 —CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —, —CH ⁇ CH—CH ⁇ CH—, —C(CH 3 ) ⁇ CH—CH 2 —, —CH ⁇ C(CH 3 )—CH 2 —, —C(CH 3 ) ⁇ C(CH 3 )— and —C(CH 2 CH 3 ) ⁇ CH—.
  • Preferred C 2-4 alkynylene groups are selected from the group consisting of —C ⁇ C—, —C ⁇ C—CH 2 —, —C ⁇ C—CH 2 —CH 2 —, —C ⁇ C—CH(CH 3 )—, —CH 2 —C ⁇ C—CH 2 — and —C ⁇ C—C ⁇ C—.
  • Preferred C 1-8 alkylene groups are selected from the group consisting of —CH 2 —, —CH 2 —CH 2 —, —CH(CH 3 )—, —CH 2 —CH 2 —CH 2 —, —CH(CH 3 )—CH 2 —, —CH(CH 2 CH 3 )—, —CH 2 —(CH 2 ) 2 —CH 2 —, —CH(CH 3 )—CH 2 —CH 2 —, —CH 2 —CH(CH 3 )—CH 2 —, —CH(CH 3 )—CH(CH 3 )—, —CH(CH 2 CH 3 )—CH 2 —, —C(CH 3 ) 2 —CH 2 —, —CH(CH 2 CH 2 CH 3 )—, —C(CH 3 )(CH 2 CH 3 )—, —CH 2 —(CH 2 ) 3 —CH 2 —, —CH(CH 3 )—CH 2 —CH
  • Preferred C 2-8 alkenylene groups are selected from the group consisting of —CH ⁇ CH—, —CH ⁇ CH—CH 2 —, —C(CH 3 ) ⁇ CH 2 —, —CH ⁇ CH—CH 2 —CH 2 —, —CH 2 —CH ⁇ CH—CH 2 —, —CH ⁇ CH—CH ⁇ CH—, —C(CH 3 ) ⁇ CH—CH 2 —, —CH ⁇ C(CH 3 )—CH 2 —, —C(CH 3 ) ⁇ C(CH 3 )—, —C(CH 2 CH 3 ) ⁇ CH—, —CH ⁇ CH—CH 2 —CH 2 —, —CH 2 —CH ⁇ CH 2 —CH 2 —, —CH ⁇ CH ⁇ CH—CH 2 —CH 2 — and —CH ⁇ CH 2 —CH—CH ⁇ CH 2 —.
  • Preferred C 2-8 alkynylene groups are selected from the group consisting of —C ⁇ C—, —C ⁇ C—CH 2 —, —C ⁇ C—CH 2 —CH 2 —, —C ⁇ C—CH(CH 3 )—, —CH 2 —C ⁇ C—CH 2 —, —C ⁇ C—C ⁇ C—, —C ⁇ C—C(CH 3 ) 2 —, —C ⁇ C—CH 2 —CH 2 —CH 2 —, —CH 2 —C ⁇ C—CH 2 —CH 2 —, —C ⁇ C—C ⁇ C—CH 2 — and —C ⁇ C—CH 2 —C ⁇ C.
  • aliphatic residue refers in the sense of this invention, with respect to the corresponding residues or groups, to the single substitution or multiple substitution, e.g.
  • polysubstituted with respect to polysubstituted residues and groups includes the polysubstitution of these residues and groups either on different or on the same atoms, for example trisubstituted on the same carbon atom, as in the case of CF 3 , CH 2 CF 3 or 1,1-difluorocyclohexyl, or at various points, as in the case of CH(OH)—CH ⁇ CH—CHCl 2 or 1-chloro-3-fluorocyclohexyl.
  • a substituent can if appropriate for its part in turn be mono- or polysubstituted. The multiple substitution can be carried out using the same or using different substituents.
  • Preferred substituents of “aliphatic residue” and “aliphatic group” are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CN; ⁇ O; ⁇ NH; R 0 ; (C 1-8 alkylene)-OH; C( ⁇ O)(R 0 or H); C( ⁇ O)O(R 0 or H); C( ⁇ O)N(R 0 or H) 2 ; OH; OR 0 ; O—C( ⁇ O)—W; O—(C 1-8 alkylene)-OH; O—(C 1-8 alkylene)-O—C 1-8 alkyl; OCF 3 ; N(R 0 or H) 2 ; N(R 0 or H)—C( ⁇ O)—R 0 ; N(R 0 or H)—S( ⁇ O) 2 —R 0 ; N(R 0 or H)—C( ⁇ O)—N(R 0 or H) 2 ; SH; SCF 3 ;
  • substituents of “aliphatic residue” and “aliphatic group” are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CN; ⁇ O; C 1-8 aliphatic residue; aryl; heteroaryl; C 3-6 cycloaliphatic residue; 3 to 6 membered heterocycloaliphatic residue; aryl, heteroaryl, C 3-6 cycloaliphatic residue or 3 to 6 membered heterocycloaliphatic bridged via a C 1 aliphatic group; CHO; C( ⁇ O)—C 1-8 aliphatic residue; C( ⁇ O)aryl; C( ⁇ O)heteroaryl; CO 2 H; C( ⁇ O)O—C 1-8 aliphatic residue; C( ⁇ O)O-aryl; C( ⁇ O)O-heteroaryl; C( ⁇ O)—NH 2 ; C( ⁇ O)NH—C 1-8 aliphatic residue; C( ⁇ O)N(C 1-8 alipha
  • aliphatic residue and “aliphatic group” are selected from the group consisting of F; Cl; Br; I; CF 3 ; C( ⁇ O)—NH 2 ; C( ⁇ O)NH—C 1-8 aliphatic residue; C( ⁇ O)N(C 1-8 aliphatic residue) 2 ; OH; O—C 1-8 aliphatic residue; O—(C 1-8 aliphatic residue)-OH; O—(C 1-8 aliphatic group)-O—C 1-8 aliphatic residue; NH 2 ; NH—C 1-8 aliphatic residue; N(C 1-8 aliphatic residue) 2 ; NH—(C 1-8 aliphatic group)-OH; N(C 1-8 aliphatic residue)[(C 1-8 aliphatic group)-OH]; NH—C( ⁇ O)—C 1-8 aliphatic residue; NH—S( ⁇ O) 2 —C 1-8 aliphatic residue; N(C 1-8 aliphatic residue; N
  • Preferred substituents of “cycloaliphatic residue” and “heterocycloaliphatic residue” are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CN; ⁇ O; ⁇ NH; R 0 ; C( ⁇ O)(R 0 or H); C( ⁇ O)O(R 0 or H); C( ⁇ O)N(R 0 or H) 2 ; OH; OR 0 ; O—C( ⁇ O)—W; O—(C 1-8 alkyl)-OH; O—(C 1-8 alkyl)-O—C 1-8 alkyl; OCF 3 ; N(R 0 or H) 2 ; N(R 0 or H)—C( ⁇ O)—R 0 ; N(R 0 or H)—S( ⁇ O) 2 —R 0 ; N(R 0 or H)—C( ⁇ O)—N(R 0 or H) 2 ; SH; SCF 3 ; SW; S(
  • cycloaliphatic residue and “heterocycloaliphatic residue” are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CN; ⁇ O; C 1-8 aliphatic residue; aryl; heteroaryl; C 3-6 cycloaliphatic residue; 3 to 6 membered heterocycloaliphatic residue; aryl, heteroaryl, C 3-6 cycloaliphatic residue or 3 to 6 membered heterocycloaliphatic bridged via a C 1 aliphatic group; CHO; C( ⁇ O)—C 1-8 aliphatic residue; C( ⁇ O)aryl; C( ⁇ O)heteroaryl; CO 2 H; C( ⁇ O)O—C 1-8 aliphatic residue; C( ⁇ O)O-aryl; C( ⁇ O)O-heteroaryl; CONH 2 ; C( ⁇ O)NH—C 1-8 aliphatic residue; C( ⁇ O)N(C 1
  • aryl and “heteroaryl”
  • the term “mono- or polysubstituted” refers in the sense of this invention, with respect to the corresponding residues or groups, to the single substitution or multiple substitution, e.g.
  • aryl and heteroaryl are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CN; R 0 ; C( ⁇ O)(R 0 or H); C( ⁇ O)O(R 0 or H); C( ⁇ O)N(R 0 or H) 2 ; OH; OR 0 ;
  • aryl and “heteroaryl” are selected from the group consisting of F; Cl; Br; I; NO 2 ; CF 3 ; CF 2 H; CFH 2 ; CN; C 1-8 aliphatic residue; aryl; heteroaryl; C 3-6 cycloaliphatic residue; 3 to 6 membered heterocycloaliphatic residue; aryl, heteroaryl, C 3-6 cycloaliphatic residue or 3 to 6 membered heterocycloaliphatic bridged via a C 1-4 aliphatic group; (C 1-8 aliphatic group)-O—C 1-8 aliphatic residue; CHO; C( ⁇ O)—C 1-8 aliphatic residue; C( ⁇ O)aryl; C( ⁇ O)heteroaryl; CO 2 H; C( ⁇ O)O—C 1-8 aliphatic residue; C( ⁇ O)O-aryl; C( ⁇ O)O-heteroaryl; CONH 2 ; C( ⁇ O)O-aryl;
  • the NH—C 1-10 aliphatic residue can then for its part be resubstituted, for example with Cl (3 rd generation substituent). Overall, this produces the functional group R 1 ⁇ C 1-10 aliphatic residue-NH—C 1-10 aliphatic residue, wherein the C 1-10 aliphatic residue of the NH—C 1-10 aliphatic residue is substituted by Cl.
  • the 3 rd generation substituents may not be resubstituted, i.e. there are then no 4 th generation substituents.
  • the 2 nd generation substituents may not be resubstituted, i.e. there are then not even any 3 rd generation substituents.
  • the functional groups for R 1 to R 9 can each if appropriate be substituted; however, the respective substituents may then for their part not be resubstituted.
  • the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl residue, respectively unsubstituted or mono- or polysubstituted, or which form together with the carbon atom(s) or heteroatom(s) connecting them, as the ring member or as the ring members, a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted.
  • Both these aryl or heteroaryl residues and the (hetero)aromatic ring systems formed in this way can if appropriate be condensed with a cycloaliphatic, preferably a C 3-6 cycloaliphatic residue, or heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, or with aryl or heteroaryl, e.g.
  • a C 3-6 cycloaliphatic residue such as cyclopentyl, or a 3 to 6 membered heterocycloaliphatic residue such as morpholinyl, or an aryl such as phenyl, or a heteroaryl such as pyridyl, wherein the cycloaliphatic or heterocycloaliphatic residues, aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
  • the compounds according to the invention are defined by substituents which are or carry a cycloaliphatic residue or a heterocycloaliphatic residue, respectively, in each case unsubstituted or mono- or polysubstituted, or which form together with the carbon atom(s) or heteroatom(s) connecting them, as the ring member or as the ring members, a ring, for example a cycloaliphatic or a heterocycloaliphatic ring system.
  • Both these cycloaliphatic or heterocycloaliphatic ring systems and the (hetero)cycloaliphatic ring systems formed in this manner can if appropriate be condensed with aryl or heteroaryl, preferably selected from the group consisting of phenyl, pyridyl and thienyl, or with a cycloaliphatic residue, preferably a C 3-6 cycloaliphatic residue, or a heterocycloaliphatic residue, preferably a 3 to 6 membered heterocycloaliphatic residue, e.g.
  • aryl such as phenyl, or a heteroaryl such as pyridyl, or a cycloaliphatic residue such as cyclohexyl, or a heterocycloaliphatic residue such as morpholinyl, wherein the aryl or heteroaryl residues or cycloaliphatic or heterocycloaliphatic residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted.
  • R 1 and R 2 denote a 3 to 10 membered heterocycloaliphatic residue
  • the 3 to 10 membered heterocycloaliphatic residue can e.g. represent morpholinyl for R 1 and can represent piperazinyl for R 2 .
  • this residue can have respectively different meanings for various substituents.
  • (R 0 or H) within a residue means that R 0 and H can occur within this residue in any possible combination.
  • the residue “N(R 0 or H) 2 ” can represent “NH 2 ”, “NHR 0 ” and)“N(R 0 ) 2 ”.
  • R 0 can respectively have the same or different meanings: in the present example of)“N(R 0 ) 2 ”, R 0 can for example represent aryl twice, thus producing the functional group “N(aryl) 2 ”, or R 0 can represent once aryl and once a C 1-10 aliphatic residue, thus producing the functional group “N(aryl)(C 1-10 aliphatic residue)”.
  • salt formed with a physiologically compatible acid or “salt of physiologically acceptable acids” refers in the sense of this invention to salts of the respective active ingredient with inorganic or organic acids which are physiologically compatible—in particular when used in human beings and/or other mammals.
  • physiologically acceptable acids are: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, saccharic acid, monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2, 3 or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, ⁇ -lipoic acid, acetyl glycine, hippuric acid, phosphoric acid, aspartic acid. Citric acid and hydrochloric acid are particularly preferred.
  • salt formed with a physiologically compatible base or “salt of physiologically acceptable bases” refers in the sense of this invention to salts of the respective compound according to the invention—as an anion, e.g. upon deprotonation of a suitable functional group—with at least one cation or base preferably with at least one inorganic cation which are physiologically acceptable in particular when used in human beings and/or other mammals.
  • inhibittion in the sense of this invention means to retard or lessen.
  • preferred embodiments of the compound according to the invention of general formula (I) have general formulae (I-e), (I-f), (I-g), (I-h), (I-i) and/or (I-j):
  • preferred embodiments of the compound according to the invention of general formula (I) have general formulae (I-k), (I-l), (I-m) and/or (I-n):
  • a particular preferred embodiment of the compound according to the invention of general formula (I) has general formulae (I-k).
  • R k represents phenyl, unsubstituted or mono- or polysubstituted with one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3 ) 2 , N(CH 3 ) 2 , CF 3 , CHF 2 and tert.-butyl, preferably phenyl mono- or disubstituted with one or two substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3 ) 2 , N(CH 3 ) 2 , CF 3 , CHF 2 and tert.-butyl, more preferably phenyl mono-substituted in meta position with one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CHCH
  • R I in each case represents one or more such as one or two substituents, preferably one substituent, more preferably one substituent in meta-position of the phenyl ring, selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3 ) 2 , N(CH 3 ) 2 , CF 3 , CHF 2 and tert.-butyl, more preferably selected from the group consisting of F, Cl, Br, I, OH, O—CH 3 , CH 3 , CF 3 , CHF 2 and tert.-butyl, even more preferably selected from the group consisting of F, Cl, Br, I, OH, O—CH 3 , CH 3 , CF 3 , still more preferably selected from the group consisting of F, Cl, OH, and O—CH 3 , most preferred selected from the group consisting of F and Cl, and R 2 , R 7 and R 8 have the meanings described
  • R 2 , R 7 and R 8 have the meanings described herein in connection with the compounds according to the invention and preferred embodiments thereof, preferably wherein R 2 denotes CF 3 , cyclopropyl or tert.-butyl, more preferably CF 3 or tert.-butyl, even more preferably CF 3 , preferably wherein R 8 denotes F, Cl, CH 3 or H, more preferably wherein R 8 denotes H, preferably wherein R 7 is selected from the group consisting of CH 3 , C 2 H 5 , CH 2 —OH, C 2 H 4 —OH, CH(OH)—CH 2 —OH, CH 2 —O—CH 3 , C 2 H 4 —O—CH 3 , CH 2 —O—CH 2 —OH, CH 2 —O—C 2 H 4 —OH, CH 2 —O—CH 2 —O—CH 3 , CH 2 —O—C 2 H 4 —OH, CH 2 —O—CH 2 —O
  • R 1 of general formula (I) is ⁇ H.
  • OCF 3 C 1-4 alkyl, C 1-4 alkylene-O—C 1-4 -alkyl, CF 3 , CF 2 H, CFH 2 , SH, S—C 1-4 alkyl, SCF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , phenyl and pyridyl, wherein phenyl or pyridyl are respectively unsubstituted or mono- or polysubstituted with one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO 2 , CN, OH, O—C 1-4 alkyl, OCF 3 , C 1-4 alkyl, C( ⁇ O)—OH, CF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , SH, S—C 1-4 alkyl, SCF 3 and S( ⁇ O) 2 OH.
  • R 1 represents substructure (T1), wherein o denotes 0.
  • OCF 3 C 1-4 alkyl, C 1-4 alkylene-O—C 1-4 -alkyl, CF 3 , CF 2 H, CFH 2 , SH, S—C 1-4 alkyl, SCF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , phenyl and pyridyl, wherein phenyl or pyridyl are respectively unsubstituted or mono- or polysubstituted with one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO 2 , CN, OH, O—C 1-4 alkyl, OCF 3 , C 1-4 alkyl, CF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , SH, S—C 1-4 alkyl, and SCF 3 .
  • OCF 3 C 1-4 alkyl, C 1-4 alkylene-O—C 1-4 -alkyl, CF 3 , CF 2 H, CFH 2 , SCF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , and phenyl, wherein phenyl is unsubstituted or mono- or polysubstituted with one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—C 1-4 alkyl, OCF 3 , C 1-4 alkyl, CF 3 , NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , and SCF 3 .
  • R 1 represents phenyl, unsubstituted or mono- or polysubstituted with one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3 ) 2 , N(CH 3 ) 2 , CF 3 , CHF 2 and tert.-butyl, preferably phenyl mono- or disubstituted with one or two substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3 ) 2 , N(CH 3 ) 2 , CF 3 , CHF 2 and tert.-butyl, more preferably phenyl mono-substituted in meta position with one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, O—CH 3 , CH 3 , CH(CH 3
  • R 2 of general formula (I) is ⁇ H.
  • R 2 is selected from the group consisting of tert-Butyl, CF 3 , cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, preferably from the group consisting of tert-Butyl, CF 3 and cyclopropyl, more preferably from the group consisting of tert-Butyl and CF 3 .
  • R 4a represents H, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl, wherein phenyl is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, CF 3 , methyl and methoxy;
  • R 4b represents H, methyl, or ethyl, or R 4a and R 4b together with the carbon atom connecting them form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
  • R 4a represents H, methyl, or ethyl
  • R 4b represents H, methyl, or ethyl, preferably H or methyl, more preferably H, or R 4a and R 4b together with the carbon atom connecting them form cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
  • R 4a represents H, methyl, or ethyl, more preferably H or methyl
  • R 4b represents H, methyl, or ethyl, preferably H or methyl, more preferably H.
  • Z represents N and R 4a represents H; or Z represents CR 4b and R 4a and R 4b each represent H; or Z represents CR 4b and R 4a represents methyl and R 4b represents H.
  • Z represents N and R 4a represents H; or Z represents CR 4b and R 4a and R 4b each represent H; or Z represents CR 4b and R 4a represents H and R 4b represents methyl.
  • T 1 , U 1 , V, U 2 and T 2 represent(s) a nitrogen atom, preferably only 1 of variables T 1 , U 1 , V, U 2 and T 2 represents a nitrogen atom, more preferably only U 1 of T 1 , U 1 , V, U 2 and T 2 represents a nitrogen atom, i.e. T 1 denotes C—R 5 , V denotes C—R 7 , U 2 denotes C—R 8 and T 2 denotes C—R 9 .
  • T2-a represents one or more of the substructures (T2-a), (T2-b), (T2-c), (T2-d), (T2-e), (T2-f), (T2-g), (T2-h), (T2-i), (T2-j) (T2-k), (T2-I), (T2-m), (T2-n), and/or (T2-o)
  • R 5 , R 6 , R 7 , R 8 and R 9 in each case independently of one another have one of the above defined meanings or have the meaning as described herein in connection with the compounds according to the invention and preferred embodiments thereof.
  • Preferred substructures of (T2) are (T2-a), (T2-b), (T2-c), (T2-e), (T24), (T2-h), (T2-i) and (T2-j), more preferred substructures of (T2) are (T2-a), (T2-b) and (T2-c), a particularly preferred substructure of (T2) is (T2-b).
  • Particularly preferred substructures of (T2-a), (T2-b) and (T2-c), respectively, are substructures (T2-a-I), (T2-b-I) and (T2-c-I)
  • R 6 , R 7 , and R 9 in each case independently of one another have one of the above defined meanings or have the meaning as described herein in connection with the compounds according to the invention and preferred embodiments thereof. Most preferred is substructure (T2-b-I).
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 7 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 5 , R 6 , R 8 and R 9 are each independently of one another selected from the group consisting of
  • R 7 is selected from the group consisting of
  • R 5 and R 9 are each independently of one another selected from the group consisting of
  • R 5 and R 9 both denote H, R 6 and R 8 are each independently of one another selected from the group consisting of
  • Particularly preferred residues for R 7 are selected from the group consisting of
  • R 7 Most preferred residues for R 7 are selected from the group consisting of CH 2 —S( ⁇ O) 2 —CH 3 , C 2 H 4 —S( ⁇ O) 2 —CH 3 , CH 2 —O—C 2 H 4 —OH, CH 2 —OH, CH 2 —CH 2 —OH, CH(OH)—CH 2 OH, CH 2 —NH—S( ⁇ O) 2 —CH 3 , CH 2 —NH—S( ⁇ O) 2 —NH 2 , C 2 H 4 —OH, NH—CH 2 —CH 2 —OH, NH—CH 2 —CH 2 —OCH 3 , and N(CH 3 )—CH 2 —CH 2 —OH; particularly most preferred are C 2 H 4 —S( ⁇ O) 2 —CH 3 , CH 2 —O—C 2 H 4 —OH, CH 2 —OH, CH 2 —NH—S( ⁇ O) 2 —CH 3 , and C 2 H 4 —OH.
  • R 5 and R 9 denote(s) H.
  • At least one, preferably one, of R 6 and R 8 denotes H.
  • R 5 and R 9 denote(s) H and at least one, preferably one, of R 6 and R 8 denotes H or both of R 6 and R 8 denote H.
  • a particularly preferred embodiment of the present invention is the compound according to the general formula (I), wherein
  • Another preferred embodiment of the present invention is the compound according to the general formula (I), wherein
  • R 3a represents H
  • V represents C—R 7 .
  • Yet another preferred embodiment of the present invention is the compound according to the general formula (I), wherein
  • a 50 percent displacement of capsaicin which is present at a concentration of 100 nM, in a FLIPR assay with CHO K1 cells which were transfected with the human VR1 gene at a concentration of less than 2,000 nM, preferably less than 1,000 nM, particularly preferably less than 300 nM, most particularly preferably less than 100 nM, even more preferably less than 75 nM, additionally preferably less than 50 nM, most preferably less than 10 nM.
  • the Ca 2+ influx is quantified in the FLIPR assay with the aid of a Ca 2+ -sensitive dye (type Fluo-4, Molecular Probes Europe BV, Leiden, the Netherlands) in a fluorescent imaging plate reader (FLIPR, Molecular Devices, Sunnyvale, USA), as described hereinafter.
  • a Ca 2+ -sensitive dye type Fluo-4, Molecular Probes Europe BV, Leiden, the Netherlands
  • FLIPR fluorescent imaging plate reader
  • substituted compounds according to the invention of the aforementioned general formula (I) and corresponding stereoisomers and also the respective corresponding acids, bases, salts and solvates are toxicologically safe and are therefore suitable as pharmaceutical active ingredients in pharmaceutical compositions.
  • the present invention therefore further relates to a pharmaceutical composition containing at least one compound according to the invention of the above-indicated formula (I), in each case if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemates or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or respectively in the form of a corresponding salt, or respectively in the form of a corresponding solvate, and also if appropriate one or more pharmaceutically compatible auxiliaries.
  • a pharmaceutical composition containing at least one compound according to the invention of the above-indicated formula (I), in each case if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemates or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or respectively in the form of
  • compositions according to the invention are suitable in particular for vanilloid receptor 1-(VR1/TRPV1) regulation, preferably for vanilloid receptor 1-(VR1/TRPV1) inhibition and/or for vanilloid receptor 1-(VR1/TRPV1) stimulation, i.e. they exert an agonistic or antagonistic effect.
  • compositions according to the invention are preferably suitable for the inhibition and/or treatment of disorders or diseases which are mediated, at least in part, by vanilloid receptors 1.
  • the pharmaceutical composition according to the invention is suitable for administration to adults and children, including toddlers and babies.
  • the pharmaceutical composition according to the invention may be found as a liquid, semisolid or solid pharmaceutical form, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example in the form of pellets or granules, if appropriate pressed into tablets, decanted in capsules or suspended in a liquid, and also be administered as much.
  • the pharmaceutical composition according to the invention conventionally contains further physiologically compatible pharmaceutical auxiliaries which can for example be selected from the group consisting of excipients, fillers, solvents, diluents, surface-active substances, dyes, preservatives, blasting agents, slip additives, lubricants, aromas and binders.
  • physiologically compatible auxiliaries and also the amounts thereof to be used depend on whether the pharmaceutical composition is to be applied orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to infections of the skin, the mucous membranes and of the eyes.
  • Preparations in the form of tablets, dragées, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral application; solutions, suspensions, easily reconstitutable dry preparations and also sprays are preferably suitable for parenteral, topical and inhalative application.
  • substituted compounds according to the invention used in the pharmaceutical composition according to the invention in a repository in dissolved form or in a plaster, agents promoting skin penetration being added if appropriate, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the respective substituted compound according to the invention also in a delayed manner.
  • compositions according to the invention are prepared with the aid of conventional means, devices, methods and process known in the art, such as are described for example in “Remington's Pharmaceutical Sciences”, A. R. Gennaro (Editor), 17 th edition, Mack Publishing Company, Easton, Pa., 1985, in particular in Part 8, Chapters 76 to 93.
  • the corresponding description is introduced herewith by way of reference and forms part of the disclosure.
  • the amount to be administered to the patient of the respective substituted compounds according to the invention of the above-indicated general formula I may vary and is for example dependent on the patient's weight or age and also on the type of application, the indication and the severity of the disorder. Conventionally 0.001 to 100 mg/kg, preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of at least one such compound according to the invention are applied per kg of the patient's body weight.
  • the pharmaceutical composition according to the invention is preferably suitable for the treatment and/or inhibition of one or more disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain; hyperalgesia; allodynia; causalgia; migraine; depression; nervous affection; axonal injuries; neurodegenerative diseases, preferably selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease; cognitive dysfunctions, preferably cognitive deficiency states, particularly preferably memory disorders; epilepsy; respiratory diseases, preferably selected from the group consisting of asthma, bronchitis and pulmonary inflammation; coughs; urinary incontinence; overactive bladder (OAB); disorders and/or injuries of the gastrointestinal tract; duodenal ulcers; gastric ulcers; irritable bowel syndrome; strokes; eye irritations; skin irritations; neurotic skin diseases; allergic skin diseases; psoriasis;
  • the pharmaceutical composition according to the invention is suitable for the treatment and/or inhibition of one or more disorders and/or diseases selected from the group consisting of pain, preferably of pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain; migraine; depression; neurodegenerative diseases, preferably selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease; cognitive dysfunctions, preferably cognitive deficiency states, particularly preferably memory disorders; inflammations, preferably inflammations of the intestine, the eyes, the bladder, the skin or the nasal mucous membrane; urinary incontinence; overactive bladder (OAB); medication dependency; misuse of medication; withdrawal symptoms in medication dependency; development of tolerance to medication, preferably development of tolerance to natural or synthetic opioids; drug dependency; misuse of drugs; withdrawal symptoms in drug dependency; alcohol dependency; misuse of alcohol and withdrawal symptoms in alcohol dependency.
  • pain preferably of pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and
  • the pharmaceutical composition according to the invention is suitable for the treatment and/or inhibition of pain, preferably of pain selected from the group consisting of acute pain, chronic pain, neuropathic pain and visceral pain.
  • the present invention further relates to a substituted compound according to general formula (I) and also if appropriate to a substituted compound according to general formula (I) and one or more pharmaceutically acceptable auxiliaries for use in vanilloid receptor 1-(VR1/TRPV1) regulation, preferably for use in vanilloid receptor 1-(VR1/TRPV1) inhibition and/or vanilloid receptor 1-(VR1/TRPV1) stimulation.
  • the present invention therefore further relates to a substituted compound according to general formula (I) and also if appropriate to a substituted compound according to general formula (I) and one or more pharmaceutically acceptable auxiliaries for use in the inhibition and/or treatment of disorders and/or diseases which are mediated, at least in part, by vanilloid receptors 1.
  • the present invention therefore further relates to a substituted compound according to general formula (I) and also if appropriate to a substituted compound according to general formula (I) and one or more pharmaceutically acceptable auxiliaries for use in the inhibition and/or treatment of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain; hyperalgesia; allodynia; causalgia; migraine; depression; nervous affection; axonal injuries; neurodegenerative diseases, preferably selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease; cognitive dysfunctions, preferably cognitive deficiency states, particularly preferably memory disorders; epilepsy; respiratory diseases, preferably selected from the group consisting of asthma, bronchitis and pulmonary inflammation; coughs; urinary incontinence; overactive bladder (OAB); disorders and/or injuries of the gastrointestinal tract; duodenal ulcers; gastric ulcer
  • a substituted compound according to general formula (I) and also if appropriate to a substituted compound according to general formula (I) and one or more pharmaceutically acceptable auxiliaries for use in the inhibition and/or treatment of pain, preferably of pain selected from the group consisting of acute pain, chronic pain, neuropathic pain and visceral pain.
  • the present invention further relates to the use of at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the preparation of a pharmaceutical composition for vanilloid receptor 1-(VR1/TRPV1) regulation, preferably for vanilloid receptor 1-(VR1/TRPV1) inhibition and/or for vanilloid receptor 1-(VR1/TRPV1) stimulation, and, further for the inhibition and/or treatment of disorders and/or diseases which are mediated, at least in part, by vanilloid receptors 1, such as e.g.
  • disorders and/or diseases selected from the group consisting of pain preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain; hyperalgesia; allodynia; causalgia; migraine; depression; nervous affection; axonal injuries; neurodegenerative diseases, preferably selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease; cognitive dysfunctions, preferably cognitive deficiency states, particularly preferably memory disorders; epilepsy; respiratory diseases, preferably selected from the group consisting of asthma, bronchitis and pulmonary inflammation; coughs; urinary incontinence; overactive bladder (OAB); disorders and/or injuries of the gastrointestinal tract; duodenal ulcers; gastric ulcers; irritable bowel syndrome; strokes; eye irritations; skin irritations; neurotic skin diseases; allergic skin diseases; psoriasis; vitiligo; herpes simplex; inflammations, preferably inflammations of the intestine
  • Another aspect of the present invention is a method for vanilloid receptor 1-(VR1/TRPV1) regulation, preferably for vanilloid receptor 1-(VR1/TRPV1) inhibition and/or for vanilloid receptor 1-(VR1/TRPV1) stimulation, and, further, a method of treatment and/or inhibition of disorders and/or diseases, which are mediated, at least in part, by vanilloid receptors 1, in a mammal, preferably of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain; hyperalgesia; allodynia; causalgia; migraine; depression; nervous affection; axonal injuries; neurodegenerative diseases, preferably selected from the group consisting of multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease; cognitive dysfunctions, preferably cognitive deficiency states, particularly preferably memory disorders; epilepsy; respiratory diseases, preferably selected from the group consisting of asthma, bron
  • the effectiveness against pain can be shown, for example, in the Bennett or Chung model (Bennett, G. J. and Xie, Y. K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain 1988, 33(1), 87-107; Kim, S. H. and Chung, J. M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 1992, 50(3), 355-363), by tail flick experiments (e.g. according to D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941)) or by the formalin test (e.g. according to D. Dubuisson et al., Pain 1977, 4, 161-174).
  • the present invention further relates to processes for preparing inventive compounds of the above-indicated general formula (I).
  • the compounds according to the present invention of general formula (I) can be prepared by a process according to which at least one compound of general formula (II),
  • Hal represents a halogen, preferably Br or Cl
  • R 4a , Y, T 1 , U 1 , V, T 2 and U 2 each have one of the foregoing meanings and Z denotes C—R 4b , wherein R 4b has one of the foregoing meanings, in a reaction medium, if appropriate in the presence of at least one suitable coupling reagent, if appropriate in the presence of at least one base, to form a compound of general formula (I),
  • R 1 , R 2 , R 3 , R 3a and n have one of the foregoing meanings, in a reaction medium, in the presence of phenyl chloroformate, if appropriate in the presence of at least one base and/or at least one coupling reagent, and said compound is if appropriate purified and/or isolated, and a compound of general formula (IV) is reacted with a compound of general formula (V),
  • R 4a , T 1 , U 1 , V, T 2 and U 2 have one of the foregoing meanings, and Z denotes N, in a reaction medium, if appropriate in the presence of at least one suitable coupling reagent, if appropriate in the presence of at least one base, to form a compound of general formula (I),
  • a reaction medium preferably selected from the group consisting of diethyl ether, tetrahydrofuran, acetonitrile,
  • All reactions which can be applied for synthesizing the compounds according to the present invention can each be carried out under the conventional conditions with which the person skilled in the art is familiar, for example with regard to pressure or the order in which the components are added. If appropriate, the person skilled in the art can determine the optimum procedure under the respective conditions by carrying out simple preliminary tests.
  • the intermediate and end products obtained using the reactions described hereinbefore can each be purified and/or isolated, if desired and/or required, using conventional methods known to the person skilled in the art. Suitable purifying processes are for example extraction processes and chromatographic processes such as column chromatography or preparative chromatography.
  • All of the process steps of the reaction sequences which can be applied for synthesizing the compounds according to the present invention as well as the respective purification and/or isolation of intermediate or end products, can be carried out partly or completely under an inert gas atmosphere, preferably under a nitrogen atmosphere.
  • substituted compounds according to the invention can be isolated both in the form of their free bases, their free acids and also in the form of corresponding salts, in particular physiologically compatible salts, i.e. physiologically acceptable salts.
  • the free bases of the respective substituted compounds according to the invention can be converted into the corresponding salts, preferably physiologically compatible salts, for example by reaction with an inorganic or organic acid, preferably with HCl, hydrobromic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, saccharic acid, monomethylsebacic acid, 5-oxoproline, hexane-1-sulfonic acid, nicotinic acid, 2, 3 or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, ⁇ -lipoic acid, acetyl glycine, hippuric acid, phosphoric acid and/or aspartic acid.
  • an inorganic or organic acid preferably with HCl
  • the free bases of the respective substituted compounds of the aforementioned general formula (I) and of corresponding stereoisomers can likewise be converted into the corresponding physiologically compatible salts using the free acid or a salt of a sugar additive, such as for example saccharin, cyclamate or acesulfame.
  • a sugar additive such as for example saccharin, cyclamate or acesulfame.
  • the free acids of the substituted compounds according to the invention can be converted into the corresponding physiologically compatible salts by reaction with a suitable base.
  • substituted compounds according to the invention and of corresponding stereoisomers can if appropriate, like the corresponding acids, the corresponding bases or salts of these compounds, also be obtained in the form of their solvates, preferably in the form of their hydrates, using conventional methods known to the person skilled in the art.
  • substituted compounds according to the invention are obtained, after preparation thereof, in the form of a mixture of their stereoisomers, preferably in the form of their racemates or other mixtures of their various enantiomers and/or diastereomers, they can be separated and if appropriate isolated using conventional processes known to the person skilled in the art. Examples include chromatographic separating processes, in particular liquid chromatography processes under normal pressure or under elevated pressure, preferably MPLC and HPLC processes, and also fractional crystallisation processes.
  • step j01 an acid halide J-0, in which Hal preferably represents Cl or Br, can be esterified using methanol to form the compound J-I by means of methods with which the person skilled in the art is familiar.
  • step j02 the methyl pivalate J-I can be converted into an oxoalkylnitrile J-II by means of methods known to the person skilled in the art, such as for example using an alkyl nitrile R 3 CH 2 —CN, if appropriate in the presence of a base.
  • step j03 the compound J-II can be converted into an amino-substituted pyrazolyl derivative J-III by means of methods known to the person skilled in the art, such as for example using hydrazine hydrate, with cyclisation.
  • step j04 the amino compound J-III can first be converted into a diazonium salt by means of methods known to the person skilled in the art, such as for example using nitrite, and the diazonium salt can be converted into a cyano-substituted pyrazolyl derivative J-IV with elimination of nitrogen using a cyanide, if appropriate in the presence of a coupling reagent.
  • step j05 the compound J-IV can be substituted in the N position by means of methods known to the person skilled in the art, for example using a halide R 1 —Hal, if appropriate in the presence of a base and/or a coupling reagent, wherein Hal is preferably Cl, Br or I, or using a boronic acid B(OH) 2 R 1 or a corresponding boronic acid ester, if appropriate in the presence of a coupling reagent and/or a base and the compound J-V can in this way be obtained.
  • a halide R 1 —Hal if appropriate in the presence of a base and/or a coupling reagent, wherein Hal is preferably Cl, Br or I
  • a boronic acid B(OH) 2 R 1 or a corresponding boronic acid ester if appropriate in the presence of a coupling reagent and/or a base and the compound J-V can in this way be obtained.
  • the substitution can be carried out using methods known to the person skilled in the art, for example with the aid of peroxy reagents and subsequent conversion into ether.
  • the substitution can be carried out by sulfonylation with sulfonyl chlorides, for example.
  • the preparation can for example be carried out by reaction with disulfides or else with sulfenyl chlorides or sulfene amides, or else by transformation into the mercaptan by means of methods known to the person skilled in the art and subsequent conversion into the thioether.
  • a second synthesis pathway in which in step k01 an ester K-0 is first reduced to form the aldehyde K-I by means of methods known to the person skilled in the art, for example using suitable hydrogenation reagents such as metal hydrides, is suitable for preparing the compound J-V.
  • step k02 the aldehyde K-I can then be reacted with a hydrazine K-V, which can be obtained in step k05, starting from the primary amine K-IV, by means of methods known to the person skilled in the art, to form the hydrazine K-II by means of methods known to the person skilled in the art with elimination of water.
  • the hydrazine K-II can be halogenated, preferably chlorinated, by means of methods known to the person skilled in the art with the double bond intact, such as for example using a chlorination reagent such as NCS, and the compound K-III can in this way be obtained.
  • step k04 the hydrazonoyl halide K-III can be converted into a cyano-substituted compound J-V by means of methods known to the person skilled in the art, such as for example using a halogen-substituted nitrile, with cyclisation.
  • step j06 the compound J-V can be hydrogenated by means of methods known to the person skilled in the art, for example using a suitable catalyst such as palladium/activated carbon or using suitable hydrogenation reagents, and the compound (II) can in this way be obtained, wherein R 3a is H.
  • a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted can be introduced into the amine (II) as R 3a ⁇ H by methods known to the person skilled in the art, such as for example mono-alkylation of a primary amine.
  • step j07 the compound (II) can be converted into the compound (IV) by means of methods known to the person skilled in the art, such as for example using phenyl chloroformate, if appropriate in the presence of a coupling reagent and/or a base.
  • phenyl chloroformate if appropriate in the presence of a coupling reagent and/or a base.
  • step j09 the amine (II) can be converted into the amide (I) (wherein Z ⁇ C—R 4b ).
  • a suitable coupling reagent for
  • the amine (II) may be converted into the amide (I) (wherein Z ⁇ C—R 4b ) by reaction of a compound (IIIa) by means of methods with which the person skilled in the art is familiar, if appropriate in the presence of a base.
  • step v1 the compound (V) can be converted into the compound (Va) by means of methods known to the person skilled in the art, such as for example using phenyl chloroformate, if appropriate in the presence of a coupling reagent and/or a base.
  • phenyl chloroformate if appropriate in the presence of a coupling reagent and/or a base.
  • the stationary phase used for the column chromatography was silica gel 60 (0.04-0.063 mm) from E. Merck, Darmstadt.
  • the mixing ratios of solvents or eluents for chromatography are specified in v/v.
  • Step j01
  • Step j02
  • Step j03
  • Step j04
  • Step j05 (method 1):
  • Step j06
  • step j05 can also be carried out as follows (method 2):
  • Step j05 (method 2):
  • Step k01
  • LAlH lithium aluminium hydride
  • 0.7 g was dissolved in dry diethyl ether (30 mL) under a protective gas atmosphere and stirred for 2 h at room temperature.
  • the suspension obtained was taken up in diethyl ether (20 mL).
  • Ethyl-2,2,2-trifluoroacetate (K-0) (1 equivalent, 10 g) was taken up in dry diethyl ether (20 mL) and added dropwise to the suspension at ⁇ 78° C. over a period of 1 h. The mixture was then the stirred for a further 2 h at ⁇ 78° C.
  • Step k05
  • Step k02
  • Step k03
  • Step k04
  • Step j06 (method 3):
  • Step a To a solution of (3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methanamine (5 g, 18 mmol) in dimethylformamide (25 mL), potassium carbonate (9.16 g, 66 mmol, 3.5 eq) was added and cooled the contents to 0° C. Then phenyl chloroformate (3.28 g (2.65 mL), 20 mmol, 1.1 equivalents) was added dropwise for 15 minutes and the overall reaction mixture was stirred for another 15 minutes at 0° C. Progress of the reaction was monitored by TLC (20% ethyl acetate-n-hexane).
  • reaction contents were filtered, filtrate was diluted with cold water (100 mL) and the product extracted with ethyl acetate (3 ⁇ 25 mL). Combined organic layer was washed with brine solution (100 mL), dried over sodium sulfate and concentrated under reduced pressure. Crude obtained was purified by column chromatography (silica gel: 100-200 mesh, eluent: 10% ethyl acetate in n-hexane) to yield the required product as a white solid (3.2 g, 45%).
  • Step a To a solution of diispropylamine (40.8 g (57 mL), 0.404 mol, 2.3 equivalents) in tetrahydrofuran (400 mL), n-BuLi (1.6 molar) (24.7 g (258.3 mL, 0.38 mol, 2.2 equivalents) was added drop wise for 2 h at 20° C. and stirred the contents for 30 45 min at 0° C. Cooled the contents to 75° C., a solution of ethyl 2,2,2-trifluoroacetate (25 g, 0.17 mol) in tetrahydrofuran (200 mL) was added drop wise for 2 h. The reaction mixture was stirred initially for 1 h at 75° C.
  • Step b A step-a product (10 g, 0.066 mol) was taken in ethanolic HCl (300 mL) and 3-chlorophenyl hydrazine (9.43 g, 0.066 mol, 1 equivalent) was added. The reaction mixture was heated to reflux for 2 h. Progress of the reaction was monitored by TLC (20% ethyl acetate in n-hexane). On completion of the reaction, reaction contents were concentrated and the residue taken in water (200 mL). Basified the contents to a pH ⁇ 12 with 1N NaOH solution and filtered the contents. Solid obtained was taken in ethyl acetate (200 mL), dried the contents over sodium sulfate and concentrated under reduced pressure to yield the required product as a red colored solid (12 g, 65%).
  • Step c Cupric bromide (11.33 g, 0.0511 mol, 1.2 equivalents) was taken in acetonitrile (176 mL) and heated to 150° C. Then n-butyl nitrite (6.59 g (7.47 mL), 0.063 mol, 1.5 eq) was added followed by a solution of step-b product (11.75 g, 0.042 mol) in acetonitrile (176 mL) was added drop wise for 30 min at 150° C. and stirred for 15 min. Progress of the reaction was monitored by TLC (5% ethyl acetate/n-hexane).
  • Step d To a solution of step-c product (13 g, 0.038 mol) in NMP (130 mL), copper cyanide (6.8 g, 0.076 mol, 2 equivalents), sodium iodide (100 mg, catalytic) were added. The reaction mixture was placed in a pre-heated oil bath at 180° C. and allowed to stir for 8 h. Progress of the reaction was monitored by TLC (5% ethyl acetate in n-hexane). On completion of the reaction, diluted the reaction contents with water (200 mL) and the product extracted with ethyl acetate (5 ⁇ 100 mL).
  • Step e To a solution of step-d product (5 g, 0.017 mol) in dry tetrahydrofuran (30 mL), Boran-tetrahydrofuran in tetrahydrofuran (70 mL) was added drop wise for 30 min at 0 5° C. Reaction mixture was slowly heated to 50° C. and allowed to stir for 12 h. Progress of the reaction was monitored by TLC (75% ethyl acetate/n-hexane). On completion of the reaction, acidified the contents to 0 5° C. with conc.HCl at 0° C. and stirred the contents for 2 h at room temperature.
  • Step a To a solution of sodium ethoxide (freshly prepared by dissolving sodium (1 g, 8.2 mmol, 1.2 equivalents) in ethanol (30 mL)), diethyl oxalate (0.92 mL, 6.85 mmol, 1 equivalent) was added at room temperature followed by addition of cyclopropyl methyl ketone (0.74 mL, 7.5 mmol, 1.1 equivalents) dropwise at 0° C. The reaction mixture was slowly warmed to room temperature and stirred for 3 h. Ice cold water (10 mL) was added and ethanol was evaporated under reduced pressure. The residual aqueous layer was diluted with 2 N aq. HCl (15 mL) and extracted with diethyl ether (2 ⁇ 25 mL). The organic layer was washed with brine solution and dried over sodium sulfate, filtered and concentrated to give a pale brown liquid (400 mg, 31%).
  • diethyl oxalate (0.92 mL,
  • Step b To a solution of step-a product (200 mg, 0.543 mmol, 1 equivalent) in ethanol (8 mL), methoxylamine hydrochloride (30% solution in water, 0.4 mL, 0.651 mmol, 1.2 equivalents) was added at room temperature and the reaction mixture stirred for 1 h. ethanol was evaporated under reduced pressure and the residual aqueous layer was extracted with ethyl acetate (15 mL). The organic layer was washed with water (10 mL), brine solution (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a pale yellow liquid (180 mg, 78%).
  • Step c A mixture of step-b product (1.1 g, 5.164 mmol, 1 equivalent) and 3-chlorophenyl hydrazine hydrochloride (1.84 g, 10.27 mmol, 2 equivalents) was taken in acetic acid (20 mL), 2-methoxy ethanol (10 mL) and the reaction mixture was heated at 105° C. for 3 h. Solvent was evaporated and the residue was extracted with ethyl acetate (60 mL). The organic layer washed with water (10 mL), brine solution (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Purification by column chromatography (silica gel: 100-200 mesh; eluent: ethyl acetate-petroleum ether (4:96)) afforded a pale brown semi solid (1.15 g, 77%).
  • Step d To a solution of step-c product (2.5 g, 8.62 mmol, 1 eq) in tetrahydrofuran (15 mL)—methanol (9 mL)-water (3 mL), lithium hydroxide (1.08 g, 25.71 mmol, 3 equivalents) was added at 0° C. and the reaction mixture was stirred for 2 h at room temperature. Solvent was evaporated and pH of the residue was adjusted to ⁇ 3 sing 2 N aqueous HCl (1.2 mL).
  • Step e To a solution of step-d product (1.4 g, 5.34 mmol, 1 equivalent) in 1,4-dioxane (30 mL), pyridine (0.25 mL, 3.2 mmol, 0.6 equivalents) and di-tert-butyl dicarbonate (1.4 mL, 6.37 mmol, 1.2 equivalents) were added at 0° C. and the resulting mixture was stirred for 30 minutes at the same temperature. Ammonium bicarbonate (0.84 g, 10.63 mmol, 2 equivalents) was added at 0° C. and the reaction mixture was stirred at room temperature overnight.
  • the reaction mixture was diluted with water (10 mL) and the aqueous layer was extracted with ethyl acetate (2 ⁇ 30 mL). The organic layer was washed with 2N HCl (20 mL), water (10 mL), brine solution (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Purification by column chromatography (silica gel: 100-200 mesh; eluent: ethyl acetate-petroleum ether (16:84)) gave a white solid (1 g, 72%).
  • Step f To a solution of step-e product (2 g, 7.66 mmol, 1 equivalent) in tetrahydrofuran (25 mL), BH 3 .DMS (1.44 mL, 15.32 mmol, 2 equivalents) was added at 0° C. and the reaction mixture was heated at 70° C. for 3 h. The reaction mixture was cooled to 0° C. and methanol (15 mL) was added and reaction mixture heated at reflux for 1 h. The reaction mixture was brought to room temperature and solvent was evaporated under reduced pressure. The residue was dissolved in ether (15 mL), cooled to 0° C.
  • Step a To a solution of 2-chloropyridine (20 g, 0.17 mol) in ethanol (100 mL), hydrazine hydrate (132 mL) was added and the reaction mixture was heated to reflux for 15 h. Progress of the reaction was monitored by TLC (40% ethyl acetate/n-hexane). As the reaction not completed, continued to reflux for another 15 h and monitored by TLC. On completion of the reaction, ethanolic hydrazine hydrochloride was distilled off completely at 100° C., residue was taken in dichloromethane (500 mL) and washed the contents with saturated sodium carbonate solution (100 mL). Combined organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product as a low melting solid (11 g, crude). The crude obtained was directly used for the next step.
  • TLC 50% ethyl acetate/n-hexane
  • Step b To a stirred solution of step-a product (11 g, crude) in ethanol (110 mL), 4,4-dimethyl-3-oxopentanenitrile (11.3 g, 0.09 mol, 0.9 equivalents) was added portion wise followed by catalytic amount of HCl. The reaction mixture was heated to 100° C. and refluxed for 6 h. Progress of the reaction was monitored by TLC (20% ethyl acetate/n-hexane). On completion of the reaction, ethanol was distilled off, residue was taken in water (200 mL) and the product extracted with ethyl acetate (2 ⁇ 100 mL).
  • Step c To a solution of step-b product (4 g, 0.01 mol) in acetonitrile (80 mL), cupric chloride (12.3 g, 0.09 mol, 5 equivalents) was added. A solution of tert-butyl nitrite (2.8 (3.3 mL), 0.023 mol, 1.5 equivalents) in acetonitrile (40 mL (total 120 mL)) was added drop wise for 10 min and the overall reaction mass was stirred for 5 h at room temperature. Progress of the reaction was monitored by TLC (10% ethyl acetate/n-hexane).
  • Step d To a stirred solution of step-c product (2.1 g, 0.008 mol) in NMP (21 mL), copper cyanide (1.56 g, 0.017 mol, 2 equivalents) was added portion wise followed by a catalytic amount of sodium iodide was added. The reaction mixture was heated to 180° C. and maintained at that temperature for 4 h. Progress of the reaction was monitored by TLC (10% ethyl acetate/n-hexane). On completion of the reaction, diluted the reaction contents with ethyl acetate, filtered the contents through celite bed and the filtrate washed with cold water (50 mL).
  • Step e To a solution of step-d product (1.5 g, 0.006 mol) in methanol (20 mL), catalytic amount of raney nickel. The reaction mixture was hydrogenated for 1 h at 60 psi. Progress of the reaction was monitored by TLC (15% ethyl acetate/n-hexane). On disappearance of the starting material, filtered the contents on celite bed and washed with methanol. To the filtrate was purified by column chromatography (silica gel: 100-200 mesh, eluent: 6% ethyl acetate in n-hexane) to yield the titled product as a cream colored oil (1.4 g, 97%).
  • Step a To a cold solution of pyridin-3-amine (40 g, 425.5 mmol) in conc. HCl (500 mL) at 0° C., a solution of NaNO 2 (35.23 g, 510.6 mmol) in water (40 mL) was added dropwise maintaining the temperature at 0° C. for 15 minutes. After addition the solution was stirred for 20 minutes. This solution was added to a solution of SnCl 2 (177.5 g, 936.3 mmol) in conc. HCl (100 mL) dropwise maintaining the temperature at 0° C. for 20 minutes and the resulting yellow solution was stirred at 0° C. for 30 minutes. The obtained yellow solid was filtered, washed with water (3 ⁇ 50 mL) and dried afford product (106.5 g, crude) as yellow solid.
  • Step b To a cold suspension of NaH (60% dispersion in oil, 29.26 g, 731.7 mmol) in 1,4-dioxane (450 mL), acetonitrile (38.46 mL, 731.7 mmol) was added dropwise at 0° C. and stirred for 30 minutes. The reaction mixture was cooled to ⁇ 5° C., ethyl 2,2,2-trifluoroacetate (83.12 g, 585.36 mmol) was slowly added and the reaction mixture allowed to stir at room temperature for 16 h.
  • the reaction mixture was cooled to 0° C., quenched with methanol (150 mL), diluted with ethyl acetate (300 mL) and pH adjusted to ⁇ 4 using diluted aqueous HCl.
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 ⁇ 250 mL).
  • the combined ethyl acetate layer was washed with water (250 mL), brine solution (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford a brown liquid (57 g).
  • the crude compound was used as such without further purification.
  • Step c A solution of step-b product (57 g, crude; 416.05 mmol) and step-a product (60.5 g, 416.05 mmol) in ethanol (650 mL) was stirred at reflux for 3 h. The reaction mixture was concentrated; the obtained residue was diluted with ethyl acetate (2 L), washed with water (2 ⁇ 500 mL), brine solution (500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Purification by column chromatography (silica gel; 100-200 mesh; eluent: 30% ethyl acetate in petroleum ether) afforded a yellow solid (31.48 g).
  • Step d To a cold suspension of potassium iodide (51.3 g, 309.21 mmol) and isoamyl nitrite (41.16 mL, 309.21 mmol) in dry acetonitrile (350 mL), a solution of step-c product (23.5 g, 103.07 mmol) in acetonitrile (100 mL) was added dropwise at 0° C. and the reaction mixture was stirred at 100° C. for 20 h. The reaction mixture was concentrated; the obtained residue was diluted with ethyl acetate (1 L), washed with water (2 ⁇ 400 mL), brine solution (200 mL), dried over sodium sulfate, filtered and concentrated to give a residue. Purification by column chromatography (silica gel; 100-200 mesh; eluent: 30% ethyl acetate in petroleum ether) afforded a pale yellow solid (16.52 g, 37%).
  • Step e To a solution of step-d product (16.5 g, 48.67 mmol) in dry NMP (150 mL), CuCN (6.53 g, 73.0 mmol) was added and the reaction mixture was stirred at 200° C. for 2 h. The reaction mixture was cooled to room temperature, quenched with ethylene diamine (50 mL) and diluted with ethyl acetate (800 mL). The obtained suspension was filtered through celite bed, washed with ethyl acetate (2 ⁇ 100 mL). The combine filtrate was washed with water (2 ⁇ 300 mL), brine solution (250 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Purification by column chromatography (silica gel; 100-200 mesh; eluent: 20-30% ethyl acetate in petroleum ether) to afford a yellow solid (5.12 g, 44%).
  • Step f To a solution of step-e product (4.5 g, 18.9 mmol) in saturated methanolic NH 3 (50 mL), Raney-Nickel (3 g, wet, washed with methanol (4 ⁇ 5 mL)) was added and the mixture was hydrogenated in a Parr hydrogenator at 40 Psi pressure at room temperature for 4 h. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The obtained residue was stirred in sat. HCl in ether (50 mL) for 2 h. Ether was decanted, the obtained solid was washed with ether (3 ⁇ 10 mL), vacuum dried to afford product compound as light brown solid (1.2 g, 23%).
  • Step a DMAP (4.25 g, 0.034 mol, 0.01 equivalents) was added to dichloromethane (3 L) and cooled the contents to ⁇ 10° C. Trifluoroacetic anhydride (765 g (510 mL), 3.2 mol, 1.05 equivalents) was added followed by ethyl vinyl ether (250 g, 3.04 mol) was added drop wise for 45 min at ⁇ 10° C. Then the overall reaction mixture was initially stirred for 8 h at 0° C. and later for overnight at room temperature. Progress of the reaction was monitored by TLC (10% ethyl acetate/n-hexane).
  • reaction contents were quenched with saturated NaHCO 3 solution (600 mL) and organic layer was separated. Aqueous layer was extracted with dichloromethane (2 ⁇ 500 mL). Combined organic layer was washed with water (2 ⁇ 1 L), dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product as a brown colored liquid (450 g, crude).
  • Step b Hydrazine dihydrochloride (225 g, 2.14 mol, 1.6 equivalents) was taken in ethanol (1.4 L) and stirred well. triethylamine (135.4 g (185.4 mL), 1.34 mol, 1 equivalent) was added drop wise for 45 min at room temperature. Then step-a product (225 g, crude) was added drop wise at room temperature and the overall reaction mixture was refluxed for overnight. Progress of the reaction was monitored by TLC (20% ethyl acetate/n-hexane). On completion of the reaction, ethanol was distilled off completely, residue was taken in ice water (500 mL) and the product extracted with ethyl acetate (2 ⁇ 400 mL). Combined extract was washed with ice water (300 mL), dried over sodium sulfate and concentrated under reduced pressure to yield the required product as and off white solid (195 g).
  • Step c NaH (33.08 g (19.85, 60%), 1.5 eq) was added to small quantity of n-hexane and stirred well for 10 min. N-hexane was decanted, dry dimethylformamide (500 mL) was added drop wise under N 2 atmosphere and stirred well. A solution of step-b product (75 g, 0.55 mol) in dimethylformamide (125 mL) was added drop wise under N 2 atmosphere. Then a solution of 4-methoxylbenzoyl chloride (86.3 g, 0.55 mol, 1 equivalent) in dimethylformamide (125 mL) was added drop wise and the overall reaction mixture was allowed to stir for 12 h at room temperature.
  • reaction contents were poured into ice water (500 mL) and the product extracted with ethyl acetate (2 ⁇ 400 mL). Then the contents were dried over sodium sulfate and concentrated under reduced pressure to yield the required product as a brown colored liquid (125 g, 88%).
  • Step d Diisopropyl amine (28.4 (39.4 mL), 1.2 equivalents) was taken in tetrahydrofuran (500 mL), stirred well and cooled the contents to 0° C. n-BuLi (234.4 mL, 1.5 eq) was added drop wise at 0° C. and cooled the contents to ⁇ 78° C. A solution of step-c product (62 g, 0.24 mol) in tetrahydrofuran (200 mL) was added drop wise for 30 min and stirred the contents for another 30 min at ⁇ 78° C.
  • reaction contents were poured into ice water (300 mL) and the aqueous layer was extracted with ethyl acetate (2 ⁇ 200 mL) in basic condition. Aqueous layer was acidified with 20% HCl solution and extracted with ethyl acetate (2 ⁇ 200 mL). Combined organic layer was dried over sodium sulfate and concentrated under reduced pressure to yield the required product as an off white solid (42 g, 58%).
  • Step e To a solution of step-d product (50 g, 0.16 mol) in dichloromethane (750 mL), catalytic amount of dimethylformamide was added and cooled to 0° C. Thionyl chloride (99.3 g (61 mL), 0.83 mol, 5 equivalents) was added drop wise for 30 min at 0° C. Overall reaction mixture was slowly heated to a reflux temperature and allowed to reflux for 2 h. Progress of the reaction was monitored by TLC (10% ethyl acetate/n-hexane). On disappearance of the starting material, dichloromethane was distilled off completely.
  • Step f LAH (4.7 g, 0.12 mol, 1 equivalent) was added to small quantity of n-hexane and stirred well for 10 min. N-hexane was decanted and tetrahydrofuran (250 mL) was added to LAH under cold condition. Then a solution of step-e product (37 g, 0.12 mol) in tetrahydrofuran (120 mL) was added drop wise for 30 min at 0° C. and reaction mixture was heated to reflux for 5 h. Progress of the reaction was monitored by TLC (50% ethyl acetate/n-hexane). As the reaction moved completely, LAH (2.3 g) was added and refluxed for another 4 h.
  • Step g To a solution of step-f product ((80 g, 0.28 mol) in dichloromethane (600 mL) cooled at 0° C., triethylamine (22.7 g (30.2 mL), 0.026 mol, 0.8 equivalents) was added drop wise for 10 min. Then Boc anhydride (61.2 g (62.5 mL), 0.28 mol, 1 eq) taken in dichloromethane (200 mL) was added drop wise for 20 30 min at 0° C. Overall reaction mixture initially stirred for 30 min at 0° C. and alter for another 30 min at room temperature. Progress of the reaction was monitored by the TLC (20% ethyl acetate/n-hexane).
  • Step h Step-g (5 g, 0.012 mol) product was taken in dichloromethane (30 mL) and cooled to 0° C. HCl gas was bubbled through the reaction mixture for 45 min at 0° C. Progress of the reaction was monitored by TLC (30% ethyl acetate/n-hexane). On completion of the reaction, dichloromethane was distilled off completely. Residue was taken in ice water (200 mL) and the product extracted with 20% ethyl acetate/n-hexane (2 ⁇ 100 mL). Aqueous layer was basified to a pH ⁇ 10 with 2N NaOH solution and extracted with ethyl acetate (5 ⁇ 100 mL). Combined organic layer was washed with water (2 ⁇ 200 mL), dried over sodium sulfate and concentrated under reduced pressure to yield the required product as an yellow colored liquid (2.4 g, 64%).
  • a chlorinating agent preferably with thionyl chloride
  • the amine of general formulae (II) (1.1 equivalents) is dissolved in dichloromethane (1 mmol of acid in 6 mL) and mixed with triethylamine (3 equivalents) at 0° C.
  • reaction mixture is stirred for 20 h at room temperature and the crude product is purified by means of column chromatography (silica gel: 100-200 mesh, eluent:n-hexane/ethyl acetate in different ratios such as 2:1) and (I) is in this way obtained.
  • Step j07/step v1
  • Step j08/step v2
  • the example compounds 1-19, 21-27, 30, 32, 50-51, 53-71, 79, 87-96, 98-115, 117, 120-121, 123-127 and 129-133 were obtained by one of the methods disclosed above and according to schemes 1 and 2.
  • the example compounds 20, 28-29, 31, 33-49, 52, 72-78, 80-86, 97, 116, 118-119, 122, 128 and 134-135 can be obtained by one of the methods disclosed above.
  • the person skilled in the art is aware which method has to be employed to obtain a particular example compound.
  • the reaction mixture was cooled to 0° C., quenched with methanol (120 mL), diluted with ethyl acetate (200 mL) and pH adjusted to ⁇ 4 using diluted aqueous HCl.
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 ⁇ 250 mL).
  • the combined ethyl acetate layer was washed with water (250 mL), brine solution (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give 4,4,4-trifluoro-3-oxobutanenitrile.
  • the crude compound was used as such without further purification. This reaction was carried out in three batches (3 ⁇ 55 g) to afford crude 4,4,4-trifluoro-3-oxobutanenitrile (B) (75 g) as a brown liquid.
  • reaction mixture was allowed to stir for 40 h.
  • the reaction mixture was concentrated under reduced pressure and the solid obtained was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/methanol 18:1) to afford N-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-2-(pyridin-2-yl)acetamide (example compound 1) (102 mg, 94%) as a white solid.
  • Examples 6, 7, 10, 11, 13, 14, 16 and 17 were prepared in a similar manner by using commercial available substituted pyridines/pyrimidines.
  • reaction mixture was quenched with saturated ammonium chloride solution (50 mL), diluted with water (60 mL) and extracted with ethyl acetate (3 ⁇ 80 mL). The total organic layer was washed with brine (50 mL). The final organic layer was dried over magnesium sulfate and was concentrated under reduced pressure to obtain crude compound which was purified by column chromatography (silica gel: 100-200 mesh, eluent: 10% ethyl acetate in n-hexane) to afford tert-butyl 2-(pyridin-2-yl)acetate (B1) (6 g, 29%).
  • dimethyl sulfate (1.95 g, 15.55 mol) in 5 mL of dry tetrahydrofuran was added at ⁇ 78° C. and was allowed to attain ambient temperature in 2 h.
  • the reaction mixture was quenched with saturated ammonium chloride solution (30 mL) and was diluted with water (50 mL) and was extracted with ethyl acetate (2 ⁇ 50 mL). The total organic layer was washed with brine (50 mL).
  • Example 8 was prepared in a similar manner by using commercial available corresponding substituted pyridine.
  • step 4 To obtain example compound 3 reaction steps 1-3 as described for example compound 2 can be carried out followed by step 4:
  • Examples 9, 12, 15, 18 19, 54 and 136 138 were prepared in a similar manner by using commercial available substituted pyridines/pyrimidines.
  • Example 20 can be prepared in a similar manner.
  • step 1 as described for example compound 4 can be carried out followed by step 2:
  • the combined organic layer was washed with brine (2 ⁇ 50 mL) and dried over anhydrous magnesium sulfate. The solvent was concentrated under reduced pressure to afford the crude compound.
  • the crude compound was purified by column chromatography (silica gel: 100-200 mesh, eluent: n-hexane) to 5-nitro-2-vinylpyridine (350 mg, 74%).
  • the concentrated reaction mixture was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/methanol 9:1) to get 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-(methylsulfonyl)ethyl)pyridin-3-yl)urea (example compound 21) (44 mg, 46%) as white solid.
  • the concentrated reaction mixture was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/methanol 19:1) to get 1-((1-(3-chlorophenyl)-3-cyclopropyl-1H-pyrazol-5-yl)methyl)-3-(5-fluoro-6-(2-(methylsulfonyl)ethyl)pyridin-3-yl)urea (example compound 24) (34 mg, 34%) as an orange solid.
  • Examples 22 and 23 were prepared in a similar manner.
  • N-((1-(3-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-2-(6-(cyanomethyl)pyridin-3-yl)propanamide (372 mg, 0.86 mmol) is dissolved in Methanol. The mixture is cooled by ice bath and slowly added di-t-butyl dicarbonate (374 mg, 1.72 mmol, 2 eq), NiCl 2 .6H 2 O (20 mg, 0.09 mmol, 0.1 eq) and NaBH 4 (227 mg, 6.00 mmol, 7 eq) and stirred for 1 h at 0° C.
  • the crude product consisted of ⁇ 20% of product and starting material according to H NMR.
  • the oil was adsorbed on silica (100 g) using dichloromethane.
  • the adsorbed silica was placed on top of a 10 cm pad of silica ( ⁇ 1 L) and the product was eluted with 20% ethyl acetate in heptane.
  • the product-containing fractions were pooled to give 3-fluoro-5-nitropicolinonitrile as a white solid (2.1 g, 15%).
  • the concentrated reaction mixture was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/methanol 9:1) to get 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(5-fluoro-6-(hydroxymethyl)pyridin-3-yl)urea (example compound 50) (12 mg, 14%) as white solid.
  • reaction mixture was concentrated and extracted with ethyl acetate (2 ⁇ 20 mL), washed with brine (30 mL), dried over sodium sulfate, concentrated and crude was purified by silica gel (100-200 mesh) column chromatography using ethyl acetate/petrol ether (1:9) as eluent to get ethyl 2-(5-nitropyridin-2-yl)acetate (0.41 g, 55%).
  • reaction mixture was quenched with ice water and extracted with ethyl acetate (30 mL), evaporated under reduced pressure and crude was purified by silica gel (100-200 mesh) column chromatography using ethyl acetate/petrol ether (1:1) as eluent to get 2-(5-nitropyridin-2-yl)ethanol (0.5 g, 25%).
  • reaction mixture was concentrated and diluted with dichloromethane (10 mL), washed water (20 mL), dried over sodium sulfate and concentrated under reduced pressure to get phenyl 6-(2-(tert-butyldimethylsilyloxy)ethyl)pyridin-3-ylcarbamate (0.195 g, 94%) as off white solid.
  • reaction mixture was concentrated and the resulting crude was purified by silica gel column chromatography (100-200 mesh) and again by preparative TLC to get 1-(6-(2-(tert-butyldimethylsilyloxy)ethyl)pyridin-3-yl)-3-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)urea (198 mg, 76%) as a white solid.
  • Reaction mixture was diluted with water ethyl acetate (200 mL 1:1), filtered on celite bed, extracted with ethyl acetate (2 ⁇ 50 mL), dried over magnesium sulfate and concentrated in vacuo.
  • the crude compound was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/petrol ether 1:2) to afford methyl 2-(6-((2-(tert-butyldimethylsilyloxy)ethoxy)methyl)pyridin-3-yl)propanoate (4.05 g, 80%) as yellow oil.
  • Example 161 can be prepared and examples 30, 51, 129, 142 and 149-151 were prepared in a similar manner.
  • Example 56 was prepared in a similar manner.
  • reaction mixture was allowed to stir for 48 h at room temperature. Reaction mixture was diluted with dichloromethane (10 mL), washed with saturated sodium carbonate solution (2 ⁇ 10 mL). The aqueous layer were extracted with dichloromethane (2 ⁇ 10 mL), combined, dried over sodium sulfate and filtered.
  • Examples 58, 59 and 61 were prepared in a similar manner.
  • 5-Bromopyrimidine-2-carboxylic acid (5 g, 24.63 mmol) was dissolved in benzene (50 mL) and thionyl chloride (5.63 mL, 73.89 mmol) was added to it in a 250 mL round bottomed flask. The reaction mixture was refluxed for 2 h at 100° C. After that thionyl chloride and benzene was removed under reduced pressure. Water was removed by making an azeotrope using benzene.
  • reaction mixture was stirred at ambient temperature for 2 h. After total consumption of starting material the reaction mixture was quenched with ammonium chloride solution (150 mL) and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
  • the crude compound was purified by column chromatography (silica gel: 100-200 mesh, eluent: 20% ethyl acetate in n-hexane) to afford 5-bromo-N-(4-fluorophenyl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2-carboxamide (6.5 g, 84%).
  • reaction mixture was refluxed for 16 h. After total consumption of starting material the reaction mixture was diluted with water and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
  • the crude N-(4-fluorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-((2-(trimethylsilyl)-ethoxy)methyl)pyrimidine-2-carboxamide was used for next step without purification (9.0 g, crude).
  • N-(4-Fluorophenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2-carboxamide (8.3 g, 17.59 mmol) was dissolved in toluene (83 mL) and methyl 2-(trifluoromethylsulfonyloxy)acrylate (4.94 g, 21.12 mmol) was added to it followed by 2 M sodium carbonate solution (35. mL) under nitrogen atmosphere. After that Pd(PPh 3 ) 4 (1.02 g, 0.87 mmol) was added to it. The reaction mixture was refluxed for 16 h.
  • reaction mixture was concentrated under reduced pressure and the solid obtained was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/diethyl ether 2:1) to afford 5-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)-N-(4-fluorophenyl)pyrimidine-2-carboxamide (example compound 63) (39 mg, 33%).
  • Examples 62, 64, 66 and 67 were prepared in a similar manner.
  • 5-Bromopyrimidine-2-carboxylic acid (5.22 g, 24.63 mmol) was dissolved in benzene (100 mL) and thionyl chloride (5.4 mL, 73.89 mmol) was added to it in a 250 mL round bottomed flask.
  • the reaction mixture was refluxed for 2 h at 100° C. After that thionyl chloride and benzene was removed under reduced pressure. Water was removed by making azeotrope using benzene.
  • the residue was dissolved in dichloromethane (100 mL) and it was added to the solution of aniline (2.27 g, 24.42 mmol) in dichloromethane (100 mL) under nitrogen atmosphere.
  • reaction mixture was stirred for 16 h at ambient temperature. After total consumption of starting material, the reaction mixture was diluted with dichloromethane (50 mL) and washed with water (2 ⁇ 100 mL) followed by sodium bicarbonate solution (2 ⁇ 100 mL) and brine (100 mL). The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude compound was purified by column chromatography (silica gel: 100-200 mesh, eluent: 20% ethyl acetate in n-hexane) to get 5-bromo-N-phenylpyrimidine-2-carboxamide (5.5 g, 77%).
  • reaction mixture was refluxed for 16 h. After total consumption of starting material the reaction mixture was diluted with water and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude N-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)pyrimidine-2-carboxamide was used for next step without purification (8.0 g, crude).
  • N-Phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-((2-(trimethylsilyl)ethoxy)-methyl)pyrimidine-2-carboxamide (7.3 g, 16.04 mmol) was dissolved in toluene (73 mL) and methyl 2-(trifluoromethylsulfonyloxy)acrylate (4.5 g, 19.25 mmol) was added to it followed by 2M sodium carbonate solution (32 mL) under nitrogen atmosphere. After that tetrakis (triphenylphosphine palladium (0) (927 mg, 0.80 mmol) was added to it. The reaction mixture was refluxed for 16 h.
  • reaction mixture was concentrated under reduced pressure and the solid obtained was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/cyclohexane 5:1) to afford 5-(1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)-N-phenyl pyrimidine-2-carboxamide (example compound 65) (118 mg, 99%).
  • reaction mixture was concentrated under reduced pressure and the solid obtained was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate) to afford 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-methoxyethylamino)pyridin-3-yl)urea (example compound 68) (178 mg, 98%) as an amber solid.
  • N-(2-methoxyethyl)-5-nitropyridin-2-amine (4.8 g, 22.84 mmol) in ethyl acetate (50 mL) was added 10% Pd/C (550 mg), then allowed to stir at room temperature for 16 h under hydrogen atmosphere.
  • the reaction mixture was passed through celite and evaporated under reduced pressure. The residue thus obtained was washed with pentane (20 mL) to get N2-(2-methoxyethyl)pyridine-2,5-diamine (3.51 g, 87%).
  • N2-(2-methoxyethyl)pyridine-2,5-diamine (3.8 g, 22.75 mmol) in acetone (35 mL) was added pyridine (5.5 mL, 68.25 mmol) followed by phenyl chloroformate (3.2 mL, 25.025 mmol) at 0° C. and stirred at room temperature for 1 h.
  • 2-chloro-5-nitropyridine (4.0 g) was stirred with 2-aminoethanol (20 mL) at room temperature for 1 h.
  • the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (2 ⁇ 50 mL), washed with brine (20 mL), dried over sodium sulfate and evaporated under vacuum. The residue was washed with n-pentane (25 mL) to get 2-(5-nitropyridin-2-ylamino)ethanol (4.16 g, 91%) as yellow solid.
  • reaction mixture was concentrated under vacuum and the residue purified (column chromatography, silica gel, ethyl acetate/methanol (4:1) as eluent) to get 1-((3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-hydroxyethylamino)pyridin-3-yl)urea (example compound 70) (125 mg, 71%).
  • Examples 72, 78, 80, 81 and 154-158 were prepared in a similar manner.
  • Examples 73-77 and 82-86 can be prepared in a similar manner.
  • Step 1-3 see example compound 70.
  • reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL), washed with brine, dried over sodium sulfate and evaporated. The residue was purified by washing with ether (5 mL), dichloromethane (10 mL) to get 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-hydroxyethylamino)pyridin-3-yl)urea (example compound 71) (77.7 mg, 54%) as pale pink solid.
  • the concentrated reaction mixture was purified by column chromatography (silica gel: 100-200 mesh, eluent: ethyl acetate/methanol 10:1) to get 1-((1-(3,4-difluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(2-hydroxyethylamino)pyridin-3-yl)urea (example compound 79) (46 mg, 59%) as white solid.
  • N2-(2-methoxyethyl)-N2-methylpyridine-2,5-diamine 2.0 g, 11.04 mmol
  • pyridine 4.3 mL, 33.12 mmol
  • phenyl chloroformate 2.46 mL, 12.144 mmol
  • reaction mixture was diluted with dichloromethane (15 mL) and washed with water (10 mL), brine (5 mL), dried over sodium sulfate and evaporated.
  • the residue was purified (neutral alumina, eluent: methanol/chloroforme 1:49) to get 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-((2-methoxyethyl)(methyl)amino)pyridin-3-yl)urea (example compound 89) (74.8 mg, 49%) as off-white solid.
  • Example 87 was prepared in a similar manner.
  • the round bottom flask was charged with palladium(II) acetate (42 mg, 0.19 mmol), BINAP (118 mg, 0.19 mmol) and toluene. The mixture was stirred under nitrogen flow for 15 min and then was added ethyl 2-(6-chloropyridin-3-yl)propanoate (200 mg, 0.94 mmol), 4-fluorobenzamide (130 mg, 0.94 mmol) and caesium carbonate (1.225 g, 3.76 mmol). The reaction mixture was refluxed overnight and then cooled to room temperature. The mixture was filtered through a plug of celite and concentrated. The residue was diluted with ethyl acetate and washed with 10% HCl solution.
  • the round bottom flask was charged with palladium(II) acetate (84 mg, 0.37 mmol), BINAP (233 mg, 0.37 mmol) and toluene. The mixture was stirred under nitrogen flow for 15 min and then was added ethyl 2-(6-chloropyridin-3-yl)propanoate (400 mg, 1.87 mmol), 4-chlorobenzamide (291 mg, 1.87 mmol) and caesium carbonate (2.44 g, 7.49 mmol). The reaction mixture was refluxed overnight and then cooled to room temperature. The mixture was filtered through a plug of celite and concentrated. The residue was diluted with ethyl acetate and washed with 10% HCl solution.
  • Example 97 can be prepared in a similar manner.
  • reaction mixture was extracted in ethyl acetate, washed with water and aqueous layer was acidified by using dilute HCl and extracted in ethyl acetate washed with water, dried magnesium sulfate, filtered and solvent was evaporated to 2-(5-fluoro-6-(methylsulfonamido)pyridin-3-yl)propanoic acid (59 mg, 60%).
  • Examples 98-100 were prepared in a similar manner.
  • potassium tertiary butoxide (146 mg, 1.297 mmol) was taken under nitrogen atmosphere, dimethylformamide (3 mL) was added, stirred at room temperature for 10 min and then cooled to ⁇ 40° C. and commercially available 2-nitro-3-methoxypyridine (100 mg, 0.648 mmol) was added followed by dropwise addition of 2-chloro-propionic acid ethyl ester (0.0908 mL, 0.712 mmol) and stirred for 20 min. Then diluted HCl was added and stirred at room temperature for 10 min.
  • reaction mixture was extracted in ethyl acetate, washed with water and aqueous layer was acidified by using diluted HCl and extracted in ethylacetate washed with water, dried over magnesium sulfate, filtered and solvent was evaporated to afford 2-(5-methoxy-6-(methylsulfonamido)pyridin-3-yl)propanoic acid (870 mg, 60%).
  • Examples 28, 29 and example 162 can be prepared in a similar manner.
  • N,N-dimethyl-5-nitro-3-(trifluoromethyl)pyridin-2-amine 200 mg, 0.85 mmol was dissolved in methanol. 10% Pd/C (40 mg) was added to it. The resulting mixture was stirred at room temperature under hydrogen atmosphere for 1 h. The mixture was filtered through celite bed and the filtrate was concentrated under reduced pressure to afford the N2,N2-dimethyl-3-(trifluoromethyl)pyridine-2,5-diamine (60 mg, 34%).
  • N2,N2-dimethyl-3-(trifluoromethyl)pyridine-2,5-diamine 60 mg, 0.29 mmol was dissolved in acetonitrile.
  • the reaction mixture was added pyridine (0.03 mL, 0.35 mmol) and phenyl chloroformate (0.04 mL, 0.31 mmol), respectively and stirred at room temperature for 1 h.
  • the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure.
  • the crude was purified by column chromatography to give phenyl 6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-ylcarbamate (47 mg, 49%).
  • Phenyl 6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-ylcarbamate (47 mg, 0.14 mmol) and (1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methanamine (42 mg, 0.15 mmol) was dissolved in dimethyl sulfoxide. Then triethylamine (0.04 mL, 0.29 mmol) was added to it. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure.
  • Phenyl 6-(dimethylamino)-5-(trifluoromethyl)pyridin-3-ylcarbamate 39 mg, 0.12 mmol
  • (3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methanamine 34 mg, 0.13 mmol
  • triethylamine (0.03 mL, 0.24 mmol) was added to it.
  • the mixture was stirred at room temperature overnight.
  • the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure.
  • 6-(Azetidin-1-yl)pyridin-3-amine 154 mg, 1.03 mmol was dissolved in acetonitrile.
  • pyridine 0.1 mL, 1.24 mmol
  • phenyl chloroformate 0.14 mL, 1.08 mmol
  • the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure.
  • the crude was purified by column chromatography to give phenyl 6-(azetidin-1-yl)pyridin-3-ylcarbamate (123 mg, 44%).
  • Phenyl 6-(azetidin-1-yl)pyridin-3-ylcarbamate (60 mg, 0.22 mmol) and (3-tert-butyl-1-(3-chlorophenyl)-1H-pyrazol-5-yl)methanamine (62 mg, 0.23 mmol) was dissolved in dimethyl sulfoxide. Then triethylamine (0.06 mL, 0.45 mmol) was added to it. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure.
  • Example 101 was prepared in a similar manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
US13/557,941 2011-07-26 2012-07-25 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands Abandoned US20130029962A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/557,941 US20130029962A1 (en) 2011-07-26 2012-07-25 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161511752P 2011-07-26 2011-07-26
EP11006114.0 2011-07-26
EP11006114 2011-07-26
US13/557,941 US20130029962A1 (en) 2011-07-26 2012-07-25 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Publications (1)

Publication Number Publication Date
US20130029962A1 true US20130029962A1 (en) 2013-01-31

Family

ID=46640622

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/557,941 Abandoned US20130029962A1 (en) 2011-07-26 2012-07-25 Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Country Status (17)

Country Link
US (1) US20130029962A1 (ru)
EP (1) EP2736900A1 (ru)
JP (1) JP2014521616A (ru)
KR (1) KR20140049026A (ru)
CN (1) CN103842357A (ru)
AR (1) AR087301A1 (ru)
BR (1) BR112014001880A2 (ru)
CA (1) CA2842916A1 (ru)
CL (1) CL2013003816A1 (ru)
CO (1) CO6940410A2 (ru)
EA (1) EA201400161A1 (ru)
EC (1) ECSP14013164A (ru)
HK (1) HK1198697A1 (ru)
MX (1) MX2014000779A (ru)
PE (1) PE20140836A1 (ru)
WO (1) WO2013013815A1 (ru)
ZA (1) ZA201400085B (ru)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029961A1 (en) * 2011-07-26 2013-01-31 Gruenenthal Gmbh Substituted Heterocyclic Aza Compounds
WO2015090600A1 (en) * 2013-12-19 2015-06-25 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers
WO2015090603A1 (en) * 2013-12-19 2015-06-25 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides iii
US9802921B2 (en) 2013-12-19 2017-10-31 Gruenenthal Gmbh Fluoromethyl-substituted pyrrole carboxamides iv
WO2024117922A1 (en) * 2022-11-29 2024-06-06 Uniwersytet Medyczny W Lublinie N-substituted derivatives of l-(l-phenyl-3-aryl)-lff-pyrazol-4-yl)methanainine, method for their production and their applications

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786245A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
EP2736886B1 (en) 2011-07-26 2016-09-14 Boehringer Ingelheim International GmbH Substituted quinolines and their use as medicaments
US9695350B2 (en) 2013-05-31 2017-07-04 Halliburton Energy Services, Inc. Ampholyte polymeric compounds in subterranean applications
ES2672581T3 (es) * 2014-06-11 2018-06-15 Bayer Cropscience Aktiengesellschaft Proceso para la preparación de 3,5-bis(haloalquil)pirazoles por medio de la acilación de cetiminas
KR20170076673A (ko) * 2014-10-24 2017-07-04 오노 야꾸힝 고교 가부시키가이샤 Kcnq2∼5 채널 활성화제
AU2015353073B2 (en) * 2014-11-24 2018-04-19 Medifron Dbt Inc. Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II
CN104478911A (zh) * 2014-12-19 2015-04-01 成都安斯利生物医药有限公司 一种制备3-三氟甲基吡咯硼酸的方法
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
CN105523995A (zh) * 2015-12-17 2016-04-27 浙江汇能生物股份有限公司 一种咯萘啶中间体2-甲氧基-5-氨基吡啶的制备方法
CN105753783B (zh) * 2016-04-08 2017-12-15 李文淏 一种合成塞来昔布的方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
MD3570834T2 (ro) 2017-01-11 2022-04-30 Alkermes Inc Inhibitori biciclici ai histon deacetilazei
WO2019032528A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc BICYCLIC HISTONE DEACETYLASE INHIBITORS
WO2022030589A1 (ja) * 2020-08-05 2022-02-10 国立大学法人北海道大学 単座配位尿素化合物を含む配位子とそれを含むホウ素化触媒
US11999699B2 (en) * 2021-06-15 2024-06-04 Grünenthal GmbH Substituted pyrazole amides
WO2024036243A2 (en) * 2022-08-10 2024-02-15 Vettore, LLC Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171743A1 (en) * 2006-08-24 2008-07-17 Astrazeneca Ab Transcutaneous immunostimulation
JP2010083763A (ja) * 2008-09-29 2010-04-15 Mitsui Chemicals Inc ピラゾール誘導体およびその製造方法、ならびに殺菌剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011192A2 (pt) * 2009-05-07 2016-03-15 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticas substituídas como ligantes de receptor de vaniloide, composição farmacêutica, uso e processo para preparação dos referidos derivados
EP2427435B1 (en) 2009-05-07 2017-06-14 Medifron DBT Inc. Substituted phenylureas and phenylamides as vanilloid receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171743A1 (en) * 2006-08-24 2008-07-17 Astrazeneca Ab Transcutaneous immunostimulation
JP2010083763A (ja) * 2008-09-29 2010-04-15 Mitsui Chemicals Inc ピラゾール誘導体およびその製造方法、ならびに殺菌剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Damasio et al., Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1992-1996 (1996). *
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th Edition, Vol. 2, pp. 2050-2057 (1996). *
Shibata et al., CAPLUS Abstract No. 152:454093 (2010). *
Szallasi et al., Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers - Miniperspective, Journal of Medicinal Chemistry, Vol. 47, No. 11, pp. 2717-2723, May 2004. *
Valenzano et al., PubMed Abstract (Curr Med Chem. 11(24):3185-202) December 2004. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029961A1 (en) * 2011-07-26 2013-01-31 Gruenenthal Gmbh Substituted Heterocyclic Aza Compounds
WO2015090600A1 (en) * 2013-12-19 2015-06-25 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides as cav2.2 calcium channel blockers
WO2015090603A1 (en) * 2013-12-19 2015-06-25 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides iii
US9562036B2 (en) 2013-12-19 2017-02-07 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers
US9802921B2 (en) 2013-12-19 2017-10-31 Gruenenthal Gmbh Fluoromethyl-substituted pyrrole carboxamides iv
WO2024117922A1 (en) * 2022-11-29 2024-06-06 Uniwersytet Medyczny W Lublinie N-substituted derivatives of l-(l-phenyl-3-aryl)-lff-pyrazol-4-yl)methanainine, method for their production and their applications

Also Published As

Publication number Publication date
BR112014001880A2 (pt) 2017-02-21
EA201400161A1 (ru) 2014-06-30
ZA201400085B (en) 2015-07-29
EP2736900A1 (en) 2014-06-04
CN103842357A (zh) 2014-06-04
AR087301A1 (es) 2014-03-12
ECSP14013164A (es) 2014-11-28
KR20140049026A (ko) 2014-04-24
WO2013013815A1 (en) 2013-01-31
PE20140836A1 (es) 2014-08-03
CO6940410A2 (es) 2014-05-09
JP2014521616A (ja) 2014-08-28
CL2013003816A1 (es) 2014-06-20
CA2842916A1 (en) 2013-01-31
HK1198697A1 (en) 2015-05-29
WO2013013815A8 (en) 2014-01-09
MX2014000779A (es) 2014-03-27

Similar Documents

Publication Publication Date Title
US20130029962A1 (en) Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
US9120756B2 (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
US20130029961A1 (en) Substituted Heterocyclic Aza Compounds
US8334315B2 (en) Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
US20120115903A1 (en) Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
JP6422589B2 (ja) バニロイド受容体リガンドｉｉとしての置換されたオキサゾール系およびチアゾール系カルボキサミドおよび尿素誘導体
US20120046301A1 (en) Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor
US9029378B2 (en) Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands
US20130079373A1 (en) Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands
WO2013045447A1 (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
EP3130589A1 (en) Heterocyclic aza compounds
TW201311664A (zh) 以含被取代吡唑芳環之羧醯胺與尿素衍生物做為類香草素受體之配位體
AU2012289253A1 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
US20120115893A1 (en) Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUENENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRANK, ROBERT;BAHRENBERG, GREGOR;CHRISTOPH, THOMAS;AND OTHERS;SIGNING DATES FROM 20120730 TO 20120813;REEL/FRAME:028883/0475

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE